Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2022

Segment Reporting [Abstract]

Summary of Financial Information with Respect to Reportable Segments

All segment revenue is earned in the United States and there are no intersegment revenues. Additionally, the Company reports assets on a consolidated basis and does not allocate assets to its reportable segments for purposes of assessing segment performance or allocating resources. Presented below is financial information with respect to the Company’s reportable segments for the periods presented:

	Three Months Ended March 31,
	2022			2021
Segment revenues:
Software	$	33,081		$	26,340
Drug discovery		15,582			5,787
Total segment revenues	$	48,663		$	32,127
Segment gross profit:
Software	$	25,570		$	20,434
Drug discovery		2,413			(4,270	)
Total segment gross profit		27,983			16,164
Unallocated:
Research and development		(27,822	)		(21,448	)
Sales and marketing		(6,671	)		(5,239	)
General and administrative		(22,133	)		(13,389	)
Loss on equity investments		—			(1,781	)
Change in fair value		(6,164	)		24,824
Interest income		328			420
Income tax benefit (expense)		28			(74	)
Consolidated net loss	$	(34,451	)	$	(523	)

Schedule of Revenues by Geographic Area

The following table sets forth revenues by geographic area for the three months ended March 31, 2022 and 2021:

	Three Months Ended March 31,
	2022		2021
United States	$	30,275	$	16,905
Europe		12,645		10,545
Japan		1,557		1,535
Rest of World		4,186		3,142
	$	48,663	$	32,127